

#### SB 25-278: EPINEPHRINE ADMINISTRATION IN SCHOOLS

**Prime Sponsors:** 

Sen. Mullica

Rep. Stewart R.; Bradley

**Bill Outcome:** Signed into Law **Drafting number:** LLS 25-1044

Fiscal note status: The final fiscal note reflects the enacted bill.

**Fiscal Analyst:** 

Kristine McLaughlin, 303-866-4776 kristine.mclaughlin@coleg.gov

**Version:** Final Fiscal Note **Date:** August 12, 2025

### **Summary Information**

**Overview.** The bill broadens the use of epinephrine on school property by changing the phrase "epinephrine auto-injector" to "emergency-use epinephrine."

**Types of impacts.** The bill is projected to affect the following areas on a temporary basis:

State Expenditures

School Districts

**Appropriations.** For FY 2025-26, the bill requires and includes an appropriation of \$9,379 to the Department of Education.

# Table 1 State Fiscal Impacts

| Type of Impact <sup>1</sup> | Budget Year<br>FY 2025-26 | Out Year<br>FY 2026-27 |
|-----------------------------|---------------------------|------------------------|
|                             |                           |                        |
| State Expenditures          | \$11,494                  | \$0                    |
| Transferred Funds           | \$0                       | \$0                    |
| Change in TABOR Refunds     | \$0                       | \$0                    |
| Change in State FTE         | 0.1 FTE                   | 0.0 FTE                |

<sup>&</sup>lt;sup>1</sup> Fund sources for these impacts are shown in the tables below.

# Table 1A State Expenditures

| Fund Source               | Budget Year<br>FY 2025-26 | Out Year<br>FY 2026-27 |
|---------------------------|---------------------------|------------------------|
|                           |                           |                        |
| Cash Funds                | \$0                       | \$0                    |
| Federal Funds             | \$0                       | \$0                    |
| Centrally Appropriated    | \$2,115                   | \$0                    |
| <b>Total Expenditures</b> | \$11,494                  | \$0                    |
| Total FTE                 | 0.1 FTE                   | 0.0 FTE                |

### **Summary of Legislation**

The bill broadens the use of epinephrine on school property by changing the phrase "epinephrine auto-injector" to "emergency-use epinephrine." Emergency-use epinephrine is defined as a portable, disposable drug delivery device or product approved by the federal Food and Drug Administration (FDA) that contains a premeasured, single dose of epinephrine that is used to treat anaphylaxis in an emergency situation.

### **Background**

The new definition of epinephrine is inclusive of the recently FDA-approved nasal epinephrine spray.

During the 2023-24 school year, Colorado K-12 schools reported 226 anaphylaxis events that included 179 students and 47 non-students. Of those experiencing anaphylaxis, 66 percent had a known allergy, 27 percent had no known allergy, and the allergy status of 7 percent was unknown. School nurses administered 89 doses of emergency epinephrine at school, and non-school nurses administered 112 doses. Stock epinephrine was used 127 times, and a student's epinephrine was used 74 times. Of the 226 anaphylaxis events at school, 25 events did not result in school staff administering epinephrine at school. Of the 201 events, 127 events occurred in the classroom, 32 in the cafeteria, 16 on the playground, 17 in the health office, 2 on the bus, and 27 in other locations.

## **State Expenditures**

The bill increases state expenditures in the Department of Education by \$11,000 in FY 2025-26 and in any future fiscal year the FDA approves a new form of epinephrine. These costs, paid from the General Fund, are summarized in Table 2 and discussed below.

# Table 2 State Expenditures Department of Education

| Cost Component               | Budget Year<br>FY 2025-26 | Out Year<br>FY 2026-27 |
|------------------------------|---------------------------|------------------------|
|                              |                           |                        |
| Centrally Appropriated Costs | \$2,115                   | \$0                    |
| Total Costs                  | \$11,494                  | \$0                    |
| Total FTE                    | 0.1 FTE                   | 0.0 FTE                |

### **Department of Education**

CDE's Student Health Services division requires 0.1 FTE Nurse Consultant in FY 2025-26 only to update all rules, guidance documents, trainings, and reporting procedures concerning anaphylaxis treatments on school grounds to allow for the use of nasal epinephrine. This cost may reoccur in any future years when a new form of emergency epinephrine receives FDA approval, and will vary depending on how complicated the administration of the new form of epinephrine is.

### **Centrally Appropriated Costs**

Pursuant to a Joint Budget Committee policy, certain costs associated with this bill are addressed through the annual budget process and centrally appropriated in the Long Bill or supplemental appropriations bills, rather than in this bill. These costs, which include employee insurance and supplemental employee retirement payments, are shown in the expenditure table above.

### **School Districts**

Workload will minimally increase for school districts to update policies concerning epinephrine use on school property and to train staff on new anaphylaxis treatments.

### **Effective Date**

This bill was signed into law by the Governor and took effect on May 30, 2025.

## **State Appropriations**

For FY 2025-26, the bill requires and includes a General Fund appropriation of \$9,379 to the Department of Education, and 0.1 FTE.

Page 4 August 12, 2025

SB 25-278

### **State and Local Government Contacts**

Education Public Health and Environment

Judicial School Districts